Overview of CRISPR
CRISPR is an innovative technology that is changing lives and making significant impacts in the healthcare sector. CRISPR, an acronym for “Clustered Regularly Interspaced Short Palindromic Repeats,” is present in prokaryotes—tiny, unicellular organisms lacking organelles. These sequences reside in the genomes of prokaryotes, which package a cell’s DNA in clusters.
As a gene editing instrument, CRISPR is employed to alter specific sections of DNA to address serious illnesses. It is especially effective in that it aids the immune system in combatting viral infections by integrating the foreign DNA into its own genome, thus allowing it to identify and eliminate the virus during subsequent encounters. Notably, when compared to other gene editing techniques, CRISPR is considerably more accurate and straightforward to configure, facilitating an easier sequence redesign process. While traditional gene-editing tools usually utilize a single protein, CRISPR employs RNA-guided targeting alongside the Cas9 enzyme.
The Mechanism of CRISPR
CRISPR operates by leveraging a natural defense system in bacteria that enables them to detect and eradicate viral threats. When a virus infiltrates a bacterial cell (a prokaryote), the bacterium captures a fragment of the invader’s DNA and stores it within its genome as genetic “memory.” This allows the bacterium to recognize and effectively respond to subsequent infections.
In the context of gene editing, this system is modified through two essential components: the Cas9 enzyme, which acts like molecular scissors to sever DNA, and guide RNA, which steers Cas9 to the specific genetic sequence in need of modification. After the DNA is targeted and cut, the cell’s inherent repair mechanisms kick in, allowing researchers to implement changes to the genetic framework.
In contrast to earlier methods that depended on challenging-to-reprogram proteins, CRISPR’s RNA-guided approach is more adaptable, simpler to design, and extremely accurate. This ease and precision have enabled CRISPR to be utilized in various fields, including medicine, agriculture, manufacturing, and microbiology—such as manipulating microbes to enhance product yields. However, as discussed in this article, the expansion of its capabilities brings along increasing ethical dilemmas, especially concerning germline editing and genetic enhancement.
First Patient Treated with Personalized CRISPR
In February 2025, the first-ever personalized CRISPR treatment was administered to an infant named KJ to address a lack of Carbamoyl Phosphate Synthetase 1 (CPS1)—an enzyme critical for converting ammonia (produced during protein metabolism) into urea. A team spearheaded by Dr. Rebecca Ahrens-Nicklas and Dr. Kiran Musunuru at the Children’s Hospital of Philadelphia crafted this treatment following extensive years of research in gene editing and collaboration with other medical professionals.
Their research concentrated on conditions impacting the urea cycle, which results in hazardous ammonia accumulation, harming organs such as the brain and liver. They customized the treatment specifically for KJ’s type of CPS1 deficiency by utilizing preclinical findings on similar variants.
Until now, the only CRISPR therapies green-lighted by the U.S. FDA have been for more widespread conditions like sickle cell disease and beta thalassemia, affecting tens of thousands to hundreds of thousands of individuals. In KJ’s scenario, his treatment was engineered within six months post-birth, targeting his specific CPS1 variant. The team devised a base editing therapy delivered through lipid nanoparticles to his liver to remedy the defective enzyme.
The February treatment marked the first of three doses; KJ received the subsequent two in March and April 2025. Following his last dose, he has shown no serious adverse effects, demonstrates improved tolerance to dietary protein, and requires diminished medication to manage ammonia levels. Although ongoing monitoring is necessary, Ahrens-Nicklas states that the current results are encouraging.
Ethical Issues Surrounding CRISPR
Like any pioneering technology, CRISPR prompts intricate ethical discussions. Although its primary aim is to modify somatic cells to treat ailments, it can also be